Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of “Hold” from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been assigned an average recommendation of “Hold” from the thirteen research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $19.70.

Several equities research analysts have recently issued reports on AARD shares. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. B. Riley Financial lowered their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, May 15th. HC Wainwright reiterated a “neutral” rating on shares of Aardvark Therapeutics in a report on Monday, March 2nd. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a report on Monday, March 2nd. Finally, Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th.

Aardvark Therapeutics Stock Performance

Shares of Aardvark Therapeutics stock opened at $3.99 on Thursday. The stock has a market cap of $87.05 million, a price-to-earnings ratio of -1.24 and a beta of 5.11. The stock has a 50 day moving average price of $4.75 and a 200-day moving average price of $9.40. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last released its earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share (EPS) for the quarter. Sell-side analysts predict that Aardvark Therapeutics will post -3.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Aardvark Therapeutics in the second quarter worth about $42,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Aardvark Therapeutics in the fourth quarter worth about $47,000. Persistent Asset Partners Ltd bought a new position in shares of Aardvark Therapeutics in the fourth quarter worth about $56,000. New York State Common Retirement Fund bought a new position in shares of Aardvark Therapeutics in the second quarter worth about $99,000. Finally, MetLife Investment Management LLC bought a new position in shares of Aardvark Therapeutics in the fourth quarter worth about $102,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.